7 Sales Incentive Best Practices for Medical Device Companies

Introduction

Medical device sales incentive design is harder than standard quota planning because the selling environment is not just commercial. Field teams often work across long evaluation cycles, hospital review processes, clinical education needs, pricing pressure, and interactions that can raise fraud-and-abuse risk if the wrong behavior is rewarded. OIG’s current guidance makes clear that remuneration tied to referrals, purchasing, or ordering of items payable by federal health care programs requires careful scrutiny, and safe-harbor logic does not remove risk by default.

For sales managers and program owners, the useful question is not whether incentives matter. It is which field behaviors the plan is teaching people to repeat. In medical device companies, that usually means balancing revenue goals with deal quality, product mix, account development, compliance discipline, and the distinct roles of quota-carrying reps, specialists, and channel partners. McKinsey’s sales-compensation guidance supports this framing: compensation design should align the salesforce to the company’s go-to-market priorities rather than operate as a generic pay formula.

This article breaks the topic into seven practical design choices. The goal is to help you structure a medical device sales incentive program that sharpens selling focus without creating margin leakage, channel conflict, or avoidable compliance exposure..

Start with the behavior you want to reinforce

The first best practice is to design from behavior backward, not from payout mechanics forward. Incentives operate as reinforcement loops: they make some choices easier to justify and repeat than others. That means the plan should begin with a short list of behaviors the business actually wants more often, such as opening target accounts, protecting price where appropriate, expanding use within approved indications, supporting implementation, or improving product mix. McKinsey’s framework is useful here because it treats compensation as a way to steer behavior toward the selling model the company needs.

This matters in medical devices because the right behavior is highly context-dependent. An orthopedic implant business may need the field to balance case support, surgeon preference, and disciplined account development. A diagnostics business selling into lab procurement may care more about standardization, service reliability, and multistakeholder account penetration. In both cases, the plan works better when it reflects how value is actually created rather than assuming every booked order is equally valuable.

A common failure point is to start with a compensation template and retrofit strategy into it later. That usually produces a plan that looks fair in administration but weak in commercial guidance.

Match measures to the role, the sales cycle, and the economics

The second best practice is role-specific design. Medical device companies often blur frontline sellers, clinical specialists, and technical support roles into one compensation philosophy. That usually creates distortion. McKinsey’s sales-incentive guidance explicitly notes that more complex selling environments often require specialized roles and more thoughtful compensation models rather than a single quota template for everyone.

The third best practice is to choose measures that reflect both the sales cycle and the economics of the business. Paying entirely on revenue can be reasonable in some portfolios, but it can also encourage discounting or overemphasis on easy volume. Paying entirely on margin can protect economics, but it can also discourage strategic placements or slower-burn account development.

The table below is the core design choice in most medtech plans.

Decision criterion: Which measures belong in the plan for each role, based on the company’s commercial motion and economic priorities.

An example helps. If a cardiovascular device company wants to expand use within existing hospital systems, a pure new-revenue plan may under-reward the rep behaviors that matter most. A share-growth or strategic product-mix measure may fit better, provided attribution rules are clear.

Build compliance guardrails into the plan itself

The fourth best practice is to treat compliance as a design input, not a legal review at the end. OIG’s FAQ on fraud-and-abuse authorities explains that the federal anti-kickback statute can be implicated by remuneration intended to induce referrals, purchasing, leasing, or ordering of items payable by federal health care programs, and that failure to fit a safe harbor does not automatically determine legality one way or the other.

For incentive design, that means the plan should not reward behavior that looks like payment for influence over reimbursable purchasing decisions or clinical judgment. It should also avoid unmanaged spiffs, vague local side deals, or temporary incentives that bypass formal review.

AdvaMed’s current Code of Ethics centers ethical interactions with healthcare professionals on integrity, responsibility, transparency, and respect for independent clinical judgment. That does not create a compensation formula by itself, but it does reinforce the need for plans that sales leaders can explain cleanly under ethical and compliance scrutiny.

A practical control set for a sales manager is simple:

• require formal approval for temporary incentives
  
• document the business rationale and target behavior
  
• set an expiration date
  
• define who can approve exceptions
  
• separate internal rep pay from customer-facing financial arrangements
  
  

That last point matters. Paying your own field team for account growth is not the same as structuring financial benefits around customers, distributors, or healthcare professionals. If the plan blurs those lines, the governance model is already too loose.

Protect price, channel clarity, and plan simplicity

The fifth best practice is to keep pricing strategy visible in the plan. If the market is under procurement pressure, a revenue-only structure can quietly teach reps to buy volume with discounting. That may look like commercial momentum for a quarter and margin erosion over a year.

This does not mean every company should pay on margin. It means the plan should show where price discipline lives. That might be a margin threshold, reduced payout on heavily discounted deals, a separate approval gate, or product-tier weighting that discourages low-quality mix.

The sixth best practice is to write channel-credit rules before conflict appears. If a company sells through direct reps, distributors, and specialist overlays, credit logic has to be explicit. Otherwise, teams start negotiating credit informally, which creates fairness concerns, weakens forecast confidence, and makes the plan feel political.

Illustrative example: if a rep opens an account, a specialist drives clinical adoption, and a distributor completes fulfillment, the company needs a pre-defined rule for ownership and influence credit. Without one, the incentive plan starts rewarding internal negotiation rather than customer-facing execution.

Simplicity matters for the same reason. A complex plan is often defended as precise, but if managers and reps cannot predict how decisions affect payout, the plan stops functioning as guidance and becomes a payroll puzzle.

Govern exceptions, train managers, and review the plan on purpose

The seventh best practice is operational governance. OIG’s General Compliance Program Guidance describes compliance infrastructure, oversight, and the seven elements of an effective compliance approach as core building blocks for healthcare organizations and stakeholders.

For incentive design, that translates into a few practical dependencies:

1. An exception process: who can approve nonstandard arrangements, and how they are documented
   
   
2. Manager enablement: how frontline managers explain the plan and coach against it
   
   
3. Escalation rules: what happens when account credit, thresholds, or special situations are disputed
   
   
4. Review cadence: when the plan is reassessed and what triggers an interim review
   
   

This is where many otherwise solid plans break down. A national structure may be sound, but regional leaders start solving pressure locally through verbal promises, custom thresholds, or off-cycle adjustments. That usually feels efficient in the moment and expensive later.

Manager training deserves special attention. If managers can explain only how payout works, but not why the company weighted one behavior over another, the plan becomes an administrative tool instead of a commercial system.

Measure whether the plan improved the business, not just payouts

A final best practice is to measure incentive effectiveness as business-shaping logic, not just pay administration. Too many teams ask only two questions: did reps hit quota, and did payout land near budget? Those checks matter, but they do not tell you whether the plan improved selling quality.

A more useful scorecard looks at whether field behavior changed in the intended direction. Depending on the business, that may include:

• discount rates
  
• product mix
  
• account penetration
  
• ramp time for new products
  
• specialist utilization
  
• exception volume
  
• payout disputes
  
• performance spread across target and non-target accounts
  
  

Illustrative example: a company adds an accelerator for a strategic device line, then sees a spike in quarter-end discounting but flat long-term utilization. That suggests the plan rewarded ordering behavior without improving durable adoption. The problem is not payroll accuracy. The problem is design logic.

For a sales manager, that is the practical test: every metric in the plan should answer either “what behavior are we rewarding?” or “how will we know whether that behavior improved the business?”

Quick Takeaways

• Start with the behavior you want the plan to reinforce, not with a recycled payout template.
  
• Match measures to roles; quota-carrying reps, specialists, and channel-influencing roles rarely need identical incentives.
  
• Use the metric mix to show the company’s real priority, whether that is revenue, margin, launch adoption, or account growth.
  
• Build compliance review into plan design, especially for temporary incentives and exceptions.
  
• Make pricing discipline and channel-credit rules explicit, or the plan may reward discounting and internal conflict.
  
• Train managers on the logic of the plan, not just the formula.
  
• Measure whether the plan changed field behavior in the intended direction, not just whether payout stayed on budget.
  
  

Conclusion

The strongest sales incentive plans for medical device companies are not the most elaborate. They are the ones that make a small number of critical commercial choices unmistakably clear. In practice, that means deciding which behaviors deserve reinforcement, assigning the right measures to the right roles, protecting price and channel clarity, and building enough governance that exceptions do not quietly become the real plan. OIG’s current compliance guidance reinforces the importance of infrastructure, oversight, and clearly governed processes in healthcare settings.

That is also why “best practice” should not be treated as a fixed template. A capital equipment portfolio, a procedure-driven implant business, and a distributor-led consumables model can all require different incentive structures even when they operate under the same regulatory umbrella. What they share is the need for incentive logic that reflects how value is created, where the company is exposed, and which field behaviors the business can actually defend.

The most useful next question for a sales manager is not whether the plan looks competitive. It is whether the plan is teaching the field to win in the way the business now needs most.